Keystone Bio is pioneering change to diagnose, treat, modify, and prevent inflammation-driven diseases including dementia, early Alzheimer's and cardio-metabolics
Keystone Bio (KB) is an emerging biotech company continuing it’s pre-clinical and clinical development of a companion diagnostic (CDx) and precision Bio- therapeutic for the early to late treatment of the major driver of systemic inflammation in the human body-virulent strain Porphyromonas gingivalis (vPg). vPg is a previously undiagnosable, untreatable, bacterial infection in the oral cavity that releases numerous virulence factors/toxins into the blood and throughout the body. This flow of toxins trigger, disarm, and overexpress the host’s innate immune response, activating pro-inflammatory NLRP1/3 inflammasomes and dysregulating the acquired immune system leading to the progression of many systemic diseases.
In addition, Keystone Bio (KB) has provided strong and convincing evidence of both the etiologic agent vPg and mechanisms of action for the neuro-inflammatory/degenerative disease in AD (Nara et. Al 2021). KB’s work has confirmed that relatively low amounts of Pg bacteria/ bacterial DNA is residing in AD brains in enough amount to account for the florid amounts of bacterial virulence factors seen in the brain tissues (Nara et. Al 2021).
This work puts new light on the longstanding conundrum of how the vPg bacteria/pathogen from a peripheral location (the oral cavity) is playing a direct/indirect systemic role in the pathogenesis of Alzheimer’s disease -especially in regards to involving and crossing the BBB. KB and other researchers believe the large presence of Pg associated toxic protein complexes cross the BBB and overtime are damaging and disrupting the BBB, finding their way into the neuro-anatomic regions associated with sporadic Alzheimer’s disease.
Our team of entrepreneurs and medical scientists, including the world’s experts in Pg, inflammatory diseases, Alzheimer’s, cardio-metabolic disease, and dentistry is working to stop disease at its source.
Keystone Bio Leading with Science bringing Biotech, Medicine, and Dentistry together for Transformative Solutions to Substantially Improve Lives.
Unlearn is the only company creating Twintelligent RCTs™, which combine AI, Digital Twins, and novel statistical methods to enable smaller, more efficient trials. Twintelligent RCTs™ incorporate prognostic information from Digital Twins into randomized controlled trials to enable smaller control groups and generate evidence suitable for supporting regulatory decisions.
InvestHK’s vision is to strengthen Hong Kong’s status as the leading international business location in Asia. Our mission is to attract and retain foreign direct investment which is of strategic importance to the economic development of Hong Kong. In all our services, we apply the following core values: passion, integrity, professionalism, customer service, business friendliness and responsiveness.
We work with overseas and Mainland entrepreneurs, SMEs and multinationals that wish to set up an office – or expand their existing business – in Hong Kong
We offer free advice and services to support companies from the planning stage right through to the launch and expansion of their business.
InvestHK is led by the Director-General of Investment Promotion, Stephen Phillips. Based in our head office in Hong Kong, Mr Phillips is supported by the Associate Directors-General Jimmy Chiang, Chief Operating Officer Jessica Cheng and Chief Marketing Officer Edith Wong.